Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)

CAPS Rating: 5 out of 5

A global pharmaceutical company, Teva develops, produces, and markets generic drugs covering all major treatment categories.

Results 1 - 20 of 385 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar mballiet (47.85) Submitted: 4/8/2016 11:34:47 AM : Outperform Start Price: $56.12 TEVA Score: -3.80

Like their recent moves in Japan and their status as a generic drug king.

Recs

0
Member Avatar tedwarrenlives (< 20) Submitted: 4/5/2016 11:25:22 PM : Outperform Start Price: $54.55 TEVA Score: +0.95

http://www.fool.com/investing/general/2016/04/02/5-top-stocks-to-buy-in-april.aspx

Sean Williams?

Recs

0
Member Avatar kembs (76.20) Submitted: 1/5/2016 2:35:02 PM : Outperform Start Price: $64.80 TEVA Score: -19.83

Good , solid management........expected groundbreaking accomplishments ahead

Recs

0
Member Avatar jkb31 (24.24) Submitted: 11/12/2015 10:56:48 AM : Outperform Start Price: $58.75 TEVA Score: -7.03

Good Entry Point, a lot of positive things happening within the company.

Recs

0
Member Avatar Janetgaye (< 20) Submitted: 9/22/2015 5:20:33 PM : Outperform Start Price: $62.01 TEVA Score: -18.49

Buying up other drug companies,earning growth

Recs

0
Member Avatar 2trpop (91.62) Submitted: 9/17/2015 8:34:46 AM : Outperform Start Price: $63.94 TEVA Score: -18.00

fstg experiment

Recs

0
Member Avatar Herbstmd (37.01) Submitted: 8/8/2015 9:01:47 AM : Outperform Start Price: $69.57 TEVA Score: -20.33

Growing company, high tech country, well positioned to yptake advantage of American push toward using generics with obamacare and insurance rules.good dividend.

Recs

0
Member Avatar lkotkin128 (< 20) Submitted: 5/13/2015 12:49:24 PM : Outperform Start Price: $59.95 TEVA Score: -7.35

Worldwide coverage. Innovation in acquiring drugs with expiring patents, and an, apparently, very deep management team.

Recs

0
Member Avatar ELPastor (< 20) Submitted: 2/13/2015 9:57:28 AM : Outperform Start Price: $55.71 TEVA Score: -0.86

This company seems quite cyclical but appears to be improving revenue and upping its dividend over the past three years.

Recs

0
Member Avatar captainsandeen (< 20) Submitted: 1/21/2015 1:33:27 PM : Outperform Start Price: $56.98 TEVA Score: -6.33

position and knows its market

Recs

1
Member Avatar thecashmen (47.93) Submitted: 6/2/2014 6:20:06 PM : Outperform Start Price: $50.12 TEVA Score: +1.40

I work in a pharmacy and teva sell the most drugs by far. I look at their numbers and they are solid but who cares about the numbers when I see with my own two eyes that their product sell by the truckload

Recs

0
Member Avatar TerryFool (< 20) Submitted: 6/1/2014 7:53:32 PM : Outperform Start Price: $48.98 TEVA Score: +4.23

2015 EPS 4.77, PE est 10.6

Recs

0
Member Avatar afewgoodstocks11 (24.68) Submitted: 5/16/2014 5:29:19 PM : Outperform Start Price: $36.15 TEVA Score: +25.08

Div. (Yield) $1.18 (2.3%)
Current Yield . . . . . . 3.5%

Recs

0
Member Avatar SnowBawl (< 20) Submitted: 5/15/2014 7:57:08 AM : Outperform Start Price: $48.08 TEVA Score: +3.88

4 Big Elderly. Reeves.

Recs

0
Member Avatar BTE78 (51.17) Submitted: 4/24/2014 2:02:39 AM : Outperform Start Price: $48.46 TEVA Score: +2.75

It's one of these stocks that's worth a gamble and one that I'm willing to play on for the long haul.

Recs

0
Member Avatar InvestmentMAGE (37.08) Submitted: 3/22/2014 3:06:06 PM : Outperform Start Price: $47.67 TEVA Score: +3.78

John Neff Screen

Recs

0
Member Avatar DrGarnicus (51.35) Submitted: 3/11/2014 2:53:29 PM : Outperform Start Price: $47.57 TEVA Score: +4.17

Many new possibilities on the horizon.

Recs

0
Member Avatar gcswim54 (< 20) Submitted: 2/21/2014 2:08:16 AM : Outperform Start Price: $46.48 TEVA Score: +5.31

George Soros is increasing his market share here. Also it is hitting a good timing period in several generic patent expiration's. Should be a good hold for a year or so.

Recs

0
Member Avatar grahamfordummies (59.48) Submitted: 12/2/2013 5:21:13 PM : Outperform Start Price: $38.82 TEVA Score: +25.58

Copaxone (daily injection to treat Multiple Sclerosis) is facing branded and potential generic competition and is roughly 60% of current profits, the CEO just resigned and pipeline visibility is low.
So why buy it here? IY is too cheap. While all of these negatives are well known and fully baked in, there are multiple potential positives that are noy well understood. They include a broad respiratory pipeline that is starting to get increased disclosure, a broad portfolio of NTE's (new therapeutic entities) that will be more fully disclosed in a Teva Webinar on December 5th, The Proctor and Gamble JV (PGT) that sells PG's OTC products in the emerging markets, a still industry leading first to file (FTF) line up of abbreviated new drud applications (ANDA's) combines with a new generic patent expiration cycle starting in 2015 and a stabilizing European market place. All of this at 8x the 2013 comsensus. Buy.

Recs

0
Member Avatar EruditeInvestor (56.21) Submitted: 11/19/2013 7:52:45 PM : Outperform Start Price: $38.24 TEVA Score: +27.36

Teva Pharmaceutical is the only stock (a total of 50 companies) selling below its forecasted range ( $47.81 to $67.28) of my proprietary QVT Equity Valuation System. Its current dividend of $1.11 yields 2.9%. TEVA has ususally increased its dividend annually and is in Powersshares International Dividend Achievers ETF (Symbol: PID). The company is one of the largest manufacturerers of generic medicines.

Featured Broker Partners